SP-18905(SP-18905) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

2型糖尿病

原研机构

Shaman Pharmaceuticals, Inc.

在研机构-

非在研机构

Shaman Pharmaceuticals, Inc.

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C27H36O7

InChIKeyHBGRAOUXLANZCC-NQEXPJQKSA-N

CAS号186026-85-7

关联

100 项与 SP-18905 相关的临床结果

登录后查看更多信息

100 项与 SP-18905 相关的转化医学

登录后查看更多信息

100 项与 SP-18905 相关的专利（医药）

登录后查看更多信息

1

项与 SP-18905 相关的文献（医药）

1999-02-01·The Journal of pharmacology and experimental therapeutics

Novel terpenoid-type quinones isolated from Pycnanthus angolensis of potential utility in the treatment of type 2 diabetes.

Article

作者: Clark, J P ; Carlson, T J ; Reaven, G M ; Mendez, C D ; Luo, J ; Fort, D M ; Yevich, E M ; Lapresca, P ; Ubillas, R P ; King, S R ; Tsai, J ; Hector, R F ; Jolad, S D ; Cheung, J

Using an ethnomedical-based drug discovery program, two previously unknown compounds (SP-18904 and SP-18905) from Pycnanthus angolensis were isolated that lower glucose concentrations in mouse models of type 2 diabetes. SP-18904 and SP-18905 are terpenoid-type quinones that significantly lowered plasma glucose concentration (p <.05) when given orally to either ob/ob or db/db mice, both of which are hyperglycemic and hyperinsulinemic. The antihyperglycemic actions of SP-18904 and SP-18905 were associated with significant decreases in plasma insulin concentrations (p <.05), suggesting that both compounds lowered glucose by enhancing insulin-mediated glucose uptake. This was supported by the insulin suppression test in ob/ob mice. Studies in hyperglycemic, insulin-deficient mice and in vitro experiments on 3T3-L1 adipocytes further supported this conclusion. As such, these two terpenoid-type quinones represent a new class of compounds of potential use in the treatment of type 2 diabetes.

100 项与 SP-18905 相关的药物交易

登录后查看更多信息